Collaboration
Cell therapy specialist Cell Medica Ltd has signed an R&D agreement with the Centre for Cell and Gene Therapy at Baylor College of Medicine, Texas, under which the two will work together in commercialising cell therapies pioneered by the Centre.
The therapies in question are designed to prevent and treat infectious diseases in patients whose immune systems are suppressed following bone marrow transplants. The approach also has the potential for the treatment of certain forms of blood cancer.
Gregg Sando, CEO of Cell Medica, said, “The agreement with the Center for Cell and Gene Therapy will lead to co-development of cell therapy products to treat infections in immuno-suppressed patients. We will also be working together to explore the use of T cell immunotherapy for the treatment of certain forms of cancer arising from oncogenic viruses.”
Cell Medica’s own lead product, an adaptive immunotherapy for cytomegalovirus infections, is currently being tested in a Phase III clinical trial across 14 hospitals in the UK.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
